In human myeloma cell lines (HMCLs), they found NEAT1 silencing treatment increased anti-multiple myeloma drugs sensitivity, which indicated that a combination of NEAT1 silencing with Olaparib, bortezomib, carfilzomib, and melphalan showed a synergistic effect 12. This evidence concerns the gene NEAT1 and plasma cell myeloma.